Epigenetic modulation of type-1 diabetes via a dual effect on pancreatic macrophages and β cells
Epigenetic modifiers are an emerging class of anti-tumor drugs, potent in multiple cancer contexts. Their effect on spontaneously developing autoimmune diseases has been little explored. We report that a short treatment with I-BET151, a small-molecule inhibitor of a family of bromodomain-containing...
Main Authors: | Wenxian Fu, Julia Farache, Susan M Clardy, Kimie Hattori, Palwinder Mander, Kevin Lee, Inmaculada Rioja, Ralph Weissleder, Rab K Prinjha, Christophe Benoist, Diane Mathis |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2014-11-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/04631 |
Similar Items
-
Treating type-1 diabetes with an epigenetic drug
by: Yohko Kitagawa, et al.
Published: (2014-12-01) -
THE TRANSCRIPTION FACTOR NF-KB AS A THERAPEUTIC TARGET IN THE TREATMENT OF MALIGNANT TUMORS
by: K. Umezawa, et al.
Published: (2017-01-01) -
Selective Targeting of Epigenetic Readers and Histone Deacetylases in Autoimmune and Inflammatory Diseases: Recent Advances and Future Perspectives
by: Mohammed Ghiboub, et al.
Published: (2021-04-01) -
Parthenolide: suggested drug for COVID-19
by: M. Nemati, et al.
Published: (2020-11-01) -
Anti-inflammatory effect of Dieffenbachia standleyi Croat extract on lipopolysaccharide-stimulated murine macrophages
by: Hyunjun Jang, et al.
Published: (2023-12-01)